Importance of Glycemic Control in Cancer Patients with Diabetes: Treatment through End of Life
- PMID: 28966959
- PMCID: PMC5559941
- DOI: 10.4103/apjon.apjon_40_17
Importance of Glycemic Control in Cancer Patients with Diabetes: Treatment through End of Life
Abstract
Cancer patients with diabetes are at increased risk for developing infections, being hospitalized, and requiring chemotherapy reductions or stoppages. While it has been hypothesized that glycemic control increases the risk for these adverse events, few studies have explored this hypothesis. The purpose of this paper is to discuss the importance of glycemic control in patients with diabetes and cancer during treatment through end of life. Glycemic control was found to play a role; the overall level of health-related quality of life experienced by patients with cancer and diabetes, level of symptom severity experienced and can impact the overall survival of the individual. Evidence-based policies and practice guidelines also need to be developed to help clinicians manage these patients during all phases of care. Using diabetes educators and advance practice, nurses to provide management and care coordination services need to be considered. Survivorship care plans should address both cancer and diabetes management. Finally, glycemic control should continue through end of life, with the main goal of avoiding hypoglycemic events.
Keywords: Cancer; chemotherapy; diabetes; end of life; glycemic control; survivorship.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Chemotherapy and Glycemic Control in Patients with Type 2 Diabetes and Cancer: A Comparative Case Analysis.Asia Pac J Oncol Nurs. 2017 Jul-Sep;4(3):224-232. doi: 10.4103/apjon.apjon_22_17. Asia Pac J Oncol Nurs. 2017. PMID: 28695169 Free PMC article.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Patient Perceptions of Diabetes Guideline Frameworks for Individualizing Glycemic Targets.JAMA Intern Med. 2019 Dec 1;179(12):1642-1649. doi: 10.1001/jamainternmed.2019.3806. JAMA Intern Med. 2019. PMID: 31524938 Free PMC article. Clinical Trial.
-
Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.Diabetes Ther. 2020 Mar;11(3):573-584. doi: 10.1007/s13300-019-00732-w. Epub 2019 Dec 23. Diabetes Ther. 2020. PMID: 31873857 Free PMC article. Review.
-
Hospitalization as an Opportunity to Optimize Glycemic Control in Oncology Patients.Curr Diab Rep. 2019 Nov 27;19(12):149. doi: 10.1007/s11892-019-1283-6. Curr Diab Rep. 2019. PMID: 31776685 Review.
Cited by
-
A Comparative analysis of type 2 diabetes management quality indicators in cancer survivors.Asia Pac J Oncol Nurs. 2022 Jul 14;9(11):100116. doi: 10.1016/j.apjon.2022.100116. eCollection 2022 Nov. Asia Pac J Oncol Nurs. 2022. PMID: 36158707 Free PMC article.
-
Influence of Diabetes Mellitus on Oncological Outcomes for Patients Living With Cancer.Sci Diabetes Self Manag Care. 2023 Apr;49(2):163-179. doi: 10.1177/26350106231153073. Epub 2023 Feb 15. Sci Diabetes Self Manag Care. 2023. PMID: 36789641 Free PMC article. Review.
-
Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies.J Endocrinol Invest. 2025 Aug;48(8):1717-1738. doi: 10.1007/s40618-025-02586-5. Epub 2025 Apr 23. J Endocrinol Invest. 2025. PMID: 40266540 Free PMC article.
-
Fatigue and diabetes self-management among operable pancreatic cancer survivors with comorbid diabetes: comparative propensity analysis.J Cancer Surviv. 2025 Jun 4. doi: 10.1007/s11764-025-01838-w. Online ahead of print. J Cancer Surviv. 2025. PMID: 40467966
-
Diabetes and cancer co-management: patient-reported challenges, needs, and priorities.Support Care Cancer. 2023 Feb 2;31(2):145. doi: 10.1007/s00520-023-07604-x. Support Care Cancer. 2023. PMID: 36729259 Free PMC article.
References
-
- World Health Organization. Secondary World Health Organization. 2017. [Last accessed on 2017 Apr 06]. Available from: http://www.who.int/mediacentre/en/
-
- Chia VM, O’Malley CD, Danese MD, Lindquist KJ, Gleeson ML, Kelsh MA, et al. Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol. 2013;129:346–52. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources